menu
    • menu

    Company profile for NorthSea Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effec...
    NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NorthSea TherapeuticsNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Gooimeer 2-35 1411 DC Naarden
    Telephone
    Telephone
    +31 (0) 35 760 65 05
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.northseatherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179)
    NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179)

    21 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221459434/en

    BUSINESSWIRE
    21 Feb 2024
    Share Share
    NorthSea Therapeutics to Present ICONA Phase 2b Data
    NorthSea Therapeutics to Present ICONA Phase 2b Data

    10 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231110240175/en

    BUSINESSWIRE
    10 Nov 2023
    Share Share
    NorthSea Receives FDA Rare Pediatric Disease Designation for SEFA-6179
    NorthSea Receives FDA Rare Pediatric Disease Designation for SEFA-6179

    17 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231017502447/en

    BUSINESSWIRE
    17 Oct 2023
    Share Share
    NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH
    NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH

    05 Jan 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230105005550/en

    BUSINESSWIRE
    05 Jan 2023
    Share Share
    NorthSea Initiates Phase 1 Trial of SEFA-6179 in orphan indication of IFALD
    NorthSea Initiates Phase 1 Trial of SEFA-6179 in orphan indication of IFALD

    02 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220202005072/en

    BUSINESSWIRE
    02 Feb 2022
    Share Share
    Biotech startup lines up more cash to steer its NASH drug through stormy seas
    Biotech startup lines up more cash to steer its NASH drug through stormy seas

    18 Dec 2021

    // P. Schloesser ENDPTS

    https://endpts.com/biotech-startup-lines-up-more-cash-to-steer-its-nash-drug-through-stormy-seas/

    P. Schloesser ENDPTS
    18 Dec 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search